Selective pulmonary artery perfusion : A novel method for the treatment of pulmonary malignancies

M. J. Grootenboers; F. M. Schramel; J. M. Hendriks; W. J. van Boven; P. E. van Schil; B. P. van Putte

Selective pulmonary artery perfusion : A novel method for the treatment of pulmonary malignancies

M. J. Grootenboers, F. M. Schramel, J. M. Hendriks, W. J. van Boven, P. E. van Schil, B. P. van Putte

Research output: Contribution to journal › Article › Academic › peer-review

3 Citations (Scopus)

Abstract

Selective pulmonary artery perfusion (SPAP) is a modality of regional chemotherapy first investigated in the 1950's. A number of studies in animal models documented pharmacokinetic superiority with high-dose local cytostatic drug concentrations when compared to intravenous administration. Blood flow occlusion of the pulmonary artery before or after drug injection results in further increase in local drug concentrations. Animal tumor models with sarcoma and coloncarcinoma confirm anti-tumour efficacy in cytostatic SPAR In human investigations, feasibility and safety of chemotherapeutic SPAP in humans has been documented. Recent encouraging investigations of SPAP with geracitabine and blood flow occlusion in a porcine model emphasize the need for further investigations in humans with pulmonary malignancies for safety and efficacy assessments

Original language	English
Pages (from-to)	361-367
Journal	Acta chirurgica Belgica
Volume	107
Issue number	4
Publication status	Published - 2007
Externally published	Yes

Cite this

@article{f1e32c2a9ad140b680d652e49e32d664,

title = "Selective pulmonary artery perfusion : A novel method for the treatment of pulmonary malignancies",

abstract = "Selective pulmonary artery perfusion (SPAP) is a modality of regional chemotherapy first investigated in the 1950's. A number of studies in animal models documented pharmacokinetic superiority with high-dose local cytostatic drug concentrations when compared to intravenous administration. Blood flow occlusion of the pulmonary artery before or after drug injection results in further increase in local drug concentrations. Animal tumor models with sarcoma and coloncarcinoma confirm anti-tumour efficacy in cytostatic SPAR In human investigations, feasibility and safety of chemotherapeutic SPAP in humans has been documented. Recent encouraging investigations of SPAP with geracitabine and blood flow occlusion in a porcine model emphasize the need for further investigations in humans with pulmonary malignancies for safety and efficacy assessments",

author = "Grootenboers, {M. J.} and Schramel, {F. M.} and Hendriks, {J. M.} and {van Boven}, {W. J.} and {van Schil}, {P. E.} and {van Putte}, {B. P.}",

year = "2007",

language = "English",

volume = "107",

pages = "361--367",

journal = "Acta chirurgica Belgica",

issn = "0001-5458",

publisher = "ARSMB-KVBMG",

number = "4",

}

TY - JOUR

T1 - Selective pulmonary artery perfusion : A novel method for the treatment of pulmonary malignancies

AU - Grootenboers, M. J.

AU - Schramel, F. M.

AU - Hendriks, J. M.

AU - van Boven, W. J.

AU - van Schil, P. E.

AU - van Putte, B. P.

PY - 2007

Y1 - 2007

N2 - Selective pulmonary artery perfusion (SPAP) is a modality of regional chemotherapy first investigated in the 1950's. A number of studies in animal models documented pharmacokinetic superiority with high-dose local cytostatic drug concentrations when compared to intravenous administration. Blood flow occlusion of the pulmonary artery before or after drug injection results in further increase in local drug concentrations. Animal tumor models with sarcoma and coloncarcinoma confirm anti-tumour efficacy in cytostatic SPAR In human investigations, feasibility and safety of chemotherapeutic SPAP in humans has been documented. Recent encouraging investigations of SPAP with geracitabine and blood flow occlusion in a porcine model emphasize the need for further investigations in humans with pulmonary malignancies for safety and efficacy assessments

AB - Selective pulmonary artery perfusion (SPAP) is a modality of regional chemotherapy first investigated in the 1950's. A number of studies in animal models documented pharmacokinetic superiority with high-dose local cytostatic drug concentrations when compared to intravenous administration. Blood flow occlusion of the pulmonary artery before or after drug injection results in further increase in local drug concentrations. Animal tumor models with sarcoma and coloncarcinoma confirm anti-tumour efficacy in cytostatic SPAR In human investigations, feasibility and safety of chemotherapeutic SPAP in humans has been documented. Recent encouraging investigations of SPAP with geracitabine and blood flow occlusion in a porcine model emphasize the need for further investigations in humans with pulmonary malignancies for safety and efficacy assessments

M3 - Article

C2 - 17966526

SN - 0001-5458

VL - 107

SP - 361

EP - 367

JO - Acta chirurgica Belgica

JF - Acta chirurgica Belgica

IS - 4

ER -